Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bulcan.2017.06.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Successful Desensitization to Lenalidomide in Leukocytoclastic Vasculitis.
J Investig Allergol Clin Immunol
October 2024
Allergy Department, Hospital Universitario La Paz, Madrid, Spain.
A Tailored 7- to 10-Day Lenalidomide Desensitization Protocol.
J Investig Allergol Clin Immunol
February 2024
Department of Allergy, La Paz University Hospital, Madrid, Spain.
Lenalidomide Desensitization for Delayed Cutaneous Reaction: A Case Series and Review of the Literature.
J Allergy Clin Immunol Pract
May 2023
Department of Clinical Immunology and Allergy, Royal Adelaide Hospital, Adelaide, South Australia, Australia; Department of Immunopathology, SA Pathology, Adelaide, South Australia, Australia. Electronic address:
Background: Lenalidomide is commonly used for treatment of multiple myeloma (MM) as well as other hematological disorders. Cutaneous adverse reactions occur frequently and withholding lenalidomide treatment may have implications for prognosis.
Objective: To evaluate the role of lenalidomide desensitization in patients with cutaneous adverse reactions.
Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity-induced rash in patients with multiple myeloma.
Eur J Haematol
April 2023
Allergy and Clinical Immunology Unit, Department of Medicine, Hadassah Medical Organization, Faculty of Medicine, Hebrew University of Jerusalem, Israel.
Introduction And Objectives: Lenalidomide is considered a standard of care in multiple myeloma (MM) Some MM patients will develop delayed hypersensitivity to lenalidomide, which can lead to treatment discontinuation. Desensitization to lenalidomide can help these patients to complete treatment courses. Here, we aimed to review lenalidomide-treated MM patients who developed delayed hypersensitivity-induced rash and were treated with desensitization.
View Article and Find Full Text PDFTargeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma.
J Hematol Oncol
April 2022
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, USA.
Inevitable relapses remain as the major therapeutic challenge in patients with mantle cell lymphoma (MCL) despite FDA approval of multiple targeted therapies and immunotherapies. Fc gamma receptors (FcγRs) play important roles in regulating antibody-mediated immunity. FcγRIIB, the unique immune-checkpoint inhibitory member of the FcγR family, has been implicated in immune cell desensitization and tumor cell resistance to the anti-CD20 antibody rituximab and other antibody-mediated immunotherapies; however, little is known about its expression and its immune-modulatory function in patients with aggressive MCL, especially those with multi-resistance.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!